Essential listening for biotech investors: Host Carmel Fisher interviews Dr. Vuong Trieu, Chairman and CEO of Oncotelic Therapeutics Inc. (OTCQB: OTLC), who has a proven track record of generating multi-billion dollar returns in biotech.

Investment Thesis: Dr. Trieu previously delivered $2.9 billion (Abraxane®/Celgene) and $1.3 billion (Cynviloq™/NantPharma) exits.

His 500+ filed patents and 75 issued patents now anchor Oncotelic's competitive moat—a rare combination of proven value creation and late-stage asset positioning that most biotechs lack.

Key Investment Differentiators:

• Late-stage pipeline risk mitigation: Multiple assets approaching commercialization vs. typical early-stage biotech burn rates
• IP fortress strategy: Deep tumor microenvironment expertise creates defensible competitive barriers
• Accelerated regulatory pathways: Proprietary approach delivers "shortest timeline, highest chance of approval"
• Portfolio diversification: Oncology, rare diseases, and pediatric programs targeting multi-billion dollar addressable markets

Near-term Catalysts (Next 12 Months): Dr. Trieu confirms: "Our investors should be really looking forward to a lot of announcements... both from the clinical side as well as regulatory milestones such as IND approval, expansion into other indications, and partnership announcements."

Investment Opportunity: Unlike speculative biotech plays, Oncotelic combines validated leadership with late-stage assets and multiple value inflection points. Dr. Trieu explains how 25 years of operational execution experience translates into superior capital efficiency and reduced development risk.

Disclaimer:

The Harvest podcast is for informational and educational purposes only. The views and opinions expressed in this podcast are those of the hosts and guests and do not necessarily reflect the official policy or position of any company or institution mentioned. The content of this podcast does not constitute investment, legal, or tax advice.

Any strategies or investment ideas discussed may not be suitable for all investors. Listeners should conduct their own research and consult with professional advisors before making any investment decisions. Past performance is not indicative of future results.

The host, guests, and producers of this podcast may hold positions in the securities discussed. This podcast may contain forward-looking statements that are subject to risks and uncertainties. Actual results may differ materially from those projected in these forward-looking statements. Investing in securities involves risk, including the potential loss of principal. Please be aware that the stock market can be volatile and investment values can fluctuate.

By listening to this podcast, you agree to not hold the host, guests, producers, or any affiliated companies liable for any investment decisions you make.

Always do your own due diligence and invest responsibly.